A spinal-cord-patterned human neural spheroid model followed myelin damage, debris clearance and new myelin formation over weeks. In a small drug comparison, clemastine increased the share of newly formed oligodendrocytes that became myelinating cells, a cellular result rather than evidence of clinical efficacy.
An Australian academic team developed spinal-cord-patterned spheroids from human induced pluripotent stem cells and added separately differentiated macrophage-like precursors that acquired microglial features. The cultures contained neurons, astrocytes and oligodendrocytes, allowing the researchers to examine interactions involved in myelin formation. They applied lysophosphatidylcholine (LPC) to injure established myelin and then followed the cultures for up to 12 weeks.
The injury experiment tracked more than a reduction in myelin staining. After lysophosphatidylcholine exposure, myelin sheaths became fragmented and shorter. The phenotype was reproduced in a second cell line, and the researchers then followed the cultures through a recovery period. Imaging of microglia showed myelin material inside these cells, with ultrastructural observations supporting debris clearance. Average morphology across an entire spheroid was less informative than these cell-resolved measurements because individual microglial responses were heterogeneous.
To examine where replacement myelin came from, the team labeled dividing cells and traced newly formed oligodendrocytes. By eight and 12 weeks of recovery, some of these cells had developed processes associated with axons and the specialized junctions at the ends of myelin segments. Electron microscopy showed compact membrane wrapping around axons. Newly formed sheaths were thinner than those in uninjured cultures, a feature consistent with repair rather than complete restoration of the original state. Cells that had not incorporated the division label could also contribute; the experiment did not attribute all remyelination to newly generated cells.
The researchers used clemastine fumarate at 1 μM as a proof-of-concept drug comparison during an eight-week recovery period. Relative to basal-medium conditions, clemastine increased the proportion of newly generated oligodendrocytes that formed myelin. The reported drug analysis involved four to seven spheroids per condition across two independent differentiations. The measured endpoint was myelination among new cells, not a patient-level neurological outcome.
The study also compared growth-factor-supported recovery and uninjured cultures. These controls help separate drug-associated myelination from baseline maturation and injury-driven repair, but the small number of differentiation batches limits what can be inferred about reproducibility across cell lines.
The long culture period and variable baseline myelination constrain immediate use as a high-throughput screening assay. In the main 18a cell line, 69% of 29 differentiations showed moderate-to-extensive myelination, and roughly half of differentiation batches showed remyelination after injury. Cell maturity, microglial addition and the quality of initial myelination all affected the assay's consistency.
The work is most informative as a human-cell system for studying a sequence of repair events and testing whether a perturbation changes a defined cellular readout. It does not establish how well spheroid responses predict treatment effects in people with demyelinating disease.
The authors position the model as a way to examine selected candidates in detail. Baseline myelination affects how much recovery can be measured, making initial tissue quality part of interpreting a treatment response.
A four-platform comparison combined lipid imaging, liver-function measurements, expression profiling and CYP assays. Lipid accumulation did not uniformly reduce drug metabolism, and differences depended on the model and donor.
A 512-compound screen in patient-derived motor neurons identified resveratrol tetramers with neuroprotective activity. Follow-up work covered 14 iPSC lines and linked protection to changes in neuronal excitability.
